According to Fortune Business Insights, the cell and gene therapy market size was valued at USD 12.21 billion in 2025. The market is projected to grow from USD 16.45 billion in 2026 to USD 143.55 billion by 2034, exhibiting a CAGR of 31.10% during the forecast period. North America dominated the cell and gene therapy market with a market share of 52.58% in 2025.
The cell and gene therapy market is witnessing rapid expansion due to increasing research and development activities, advancements in genetic engineering, rising adoption of personalized medicine, and growing interest in innovative therapeutic approaches for complex diseases.
Continue reading for more details:
https://www.fortunebusinessinsights.com/cell-and-gene-therapy-market-114130
Market Segmentation
The cell and gene therapy market can be segmented based on therapy type, therapeutic area, end user, and geography. Based on therapy type, the market includes cell therapy and gene therapy. Cell therapy involves the use of living cells to repair, replace, or regenerate damaged tissues, while gene therapy focuses on modifying or introducing genetic material to address the underlying causes of diseases. Both approaches are becoming increasingly important in the development of advanced treatments. Based on therapeutic area, the market covers oncology, genetic disorders, neurological disorders, cardiovascular conditions, ophthalmic disorders, and other applications. Oncology represents an important area of application because researchers are increasingly investigating cell-based and gene-based approaches for difficult-to-treat cancers. Genetic disorders are also a major focus because gene therapy can potentially address disease mechanisms at their genetic source. Based on end user, the market includes hospitals, specialty clinics, research institutes, and other healthcare facilities. Hospitals and specialized treatment centers play an important role in the administration and monitoring of advanced therapies, while research institutes contribute substantially to clinical development and technological innovation.
Key Players
- Novartis AG
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- AbbVie Inc.
- AstraZeneca
- BioNTech SE
- Vertex Pharmaceuticals Incorporated
- bluebird bio, Inc.
Market Growth
The cell and gene therapy market is expanding rapidly as advances in biotechnology continue to improve the development of therapies designed to address complex and previously difficult-to-treat diseases. Increasing investment in research and development is encouraging pharmaceutical companies, biotechnology firms, academic institutions, and research organizations to explore new therapeutic approaches. The growing emphasis on personalized medicine is another important factor supporting market development. Cell and gene therapies can be designed around specific disease mechanisms and patient characteristics, creating opportunities for more targeted treatment strategies. Advances in gene editing technologies, viral and non-viral delivery systems, cell engineering, and manufacturing processes are improving the capabilities of developers and supporting the progression of innovative therapies. Increasing clinical research activity is also strengthening the pipeline of potential treatments across oncology, rare diseases, genetic disorders, and other therapeutic areas. The development of regenerative medicine is creating additional opportunities for cell-based approaches, particularly where conventional treatments may have limitations. At the same time, improvements in manufacturing technologies are helping companies address the complex requirements associated with producing personalized and genetically modified therapies. Pharmaceutical and biotechnology companies are also entering strategic collaborations, licensing agreements, and research partnerships to accelerate innovation and expand their therapeutic pipelines. Growing awareness of advanced treatment options among healthcare professionals and patients is supporting demand for innovative therapies. Regulatory agencies are also establishing frameworks to evaluate advanced therapeutic products, which can facilitate the development and commercialization of promising treatments. As scientific knowledge continues to improve, the cell and gene therapy market is expected to benefit from continued innovation, increasing clinical activity, and expanding applications across multiple disease categories.
Restraining Factors
Despite strong growth prospects, the cell and gene therapy market faces several challenges. The development and manufacturing of advanced therapies can be highly complex because these treatments often require specialized facilities, sophisticated technologies, controlled production environments, and highly trained personnel. Manufacturing consistency and quality control are particularly important because variations in biological materials and production processes can affect treatment performance. High development costs can also create barriers for smaller biotechnology companies and research organizations. The complexity of clinical development represents another challenge, as advanced therapies may require specialized clinical protocols, extended monitoring, and carefully selected patient populations. Regulatory requirements can also be demanding because cell and gene therapies involve novel mechanisms and manufacturing processes that require comprehensive evaluation. Patient access and affordability remain additional concerns, particularly for highly specialized treatments requiring extensive healthcare infrastructure. Supply-chain management can present difficulties because certain therapies require controlled transportation, specialized storage, and coordinated handling between manufacturing facilities and treatment centers. Ethical considerations related to genetic modification and the use of biological materials may also influence public acceptance and regulatory discussions. Furthermore, the availability of specialized healthcare professionals with expertise in advanced therapies can affect treatment capacity. Addressing these challenges through manufacturing innovation, improved infrastructure, regulatory collaboration, and workforce development will remain important for the continued expansion of the cell and gene therapy market.
Regional Analysis
North America is a leading region in the cell and gene therapy market, supported by advanced healthcare infrastructure, strong biotechnology capabilities, extensive research activity, and the presence of major pharmaceutical and biotechnology companies. The region has a strong ecosystem involving academic institutions, research organizations, healthcare providers, and specialized treatment centers. Continued investment in innovative therapies and clinical research is supporting the development of advanced cell and gene therapy applications.
Europe represents a significant market supported by established healthcare systems, biotechnology research capabilities, and increasing investment in advanced therapeutic technologies. Research institutions and pharmaceutical companies across the region are actively involved in the development of innovative treatments. Regulatory developments and increasing emphasis on personalized medicine are also influencing market expansion.
Asia Pacific is experiencing increasing interest in cell and gene therapy as healthcare infrastructure, biotechnology capabilities, and research activities continue to develop. Growing investments by pharmaceutical and biotechnology companies are supporting the expansion of advanced therapy development. Increasing awareness of innovative treatment approaches is also creating opportunities for market participants.
Latin America is gradually developing opportunities in the cell and gene therapy market through improvements in healthcare infrastructure, research capabilities, and access to advanced medical technologies. Increasing collaboration between healthcare institutions, research organizations, and biotechnology companies can support the introduction of innovative therapeutic approaches.
The Middle East & Africa region offers emerging opportunities as healthcare systems develop and investments in advanced medical technologies increase. Specialized healthcare facilities and research capabilities are gradually expanding, creating opportunities for the adoption of advanced therapies. Overall, the cell and gene therapy market in 2026 is being shaped by biotechnology innovation, personalized medicine, clinical research, advanced manufacturing, strategic collaborations, and increasing interest in targeted treatments for complex diseases.
Uncover Japan’s Market Trends - Explore the Latest -Cell and Gene Therapy Market - Insights-